ASTRAZENECA PLC Toevoegen aan een lijst
|
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
| 12.712,00 GBX | +0,49% |
|
-4,23% | +19,92% |
| 19:55 | AstraZeneca zegt dat proef met longkankermedicijn geen significante verbetering in algehele overleving laat zien | RE |
| 12:33 | ASTRAZENECA : UBS is niet overtuigd | ZD |
Belangrijkste concurrenten
Toevoegen aan een lijst 0 geselecteerde | Omzet ($) (Y-1) | Nettomarge (Y-1) | Bedrijfsmarge (Y-1) | ROE (Y-1) | ROA (Y-1) | Hefboom (schuld/EBITDA) (Y-1) | |
|---|---|---|---|---|---|---|---|
| 45,81 mld. | +13.01% | +31.73% | +29.77% | +11.48% | 1.66x | ||
| 34,12 mld. | +15.36% | +20.68% | +48.93% | +9.23% | 2.6x | ||
| 34,57 mld. | +36.03% | +44.16% | +88.07% | +30.12% | -0.03x | ||
| 85,16 mld. | +41.28% | +32.25% | +34.91% | +14.32% | 0.21x | ||
| 54,32 mld. | +8.95% | +45.64% | +143.18% | +14.46% | 1.82x | ||
| 60,12 mld. | +0.61% | +10.33% | +9.18% | +3.56% | 2.77x | ||
| 69,78 mld. | +19.58% | +32.77% | +45.73% | +16.71% | 0.85x | ||
| 45,44 mld. | +32.69% | +36.03% | +25.37% | +12.37% | 0.67x | ||
| 28,19 mld. | +23.83% | +47.53% | +202.85% | +12.37% | 3.07x | ||
| 58,5 mld. | +3.62% | +15.90% | +11.37% | +4.96% | 3.8x | ||
| 47,82 mld. | +12.54% | +29.42% | +13.65% | +4.27% | 0.55x | ||
| 45,01 mld. | +17.83% | +37.30% | +51.57% | +8.36% | 1.55x | ||
| 27,12 mld. | +20.89% | +38.66% | +38.46% | +13.49% | 1.34x | ||
| 39,89 mld. | +16.25% | +28.97% | +52.48% | +10.55% | 1.29x | ||
| 7,82 mld. | +29.29% | +39.52% | +21.30% | +23.34% | -1.57x | ||
| 11,27 mld. | +12.53% | +13.21% | +12.80% | +7.95% | -2.01x | ||
| 30 mld. | +3.38% | +5.02% | +2.10% | +0.36% | 4.66x | ||
| 14,86 mld. | +9.28% | +22.55% | +6.37% | +3.05% | 3.01x | ||
| 3,22 mld. | +18.85% | +21.52% | +10.99% | +9.99% | -3.66x | ||
| Gemiddelde | 39,11 mld. | +17,67% | +29,11% | +44,69% | +11,10% | 1,19x | |
| Gewogen gemiddelde per kap. | 45,9 mld. | +20,18% | +30,79% | +56,11% | +13,34% | 1,42x |
- Beurs
- Aandelen
- Koers AZN
- Sector AstraZeneca PLC
- Financiële vergelijkingen
